Early determination of potential critical quality attributes of therapeutic antibodies in developability studies through surface plasmon resonance-based relative binding activity assessment

References

• Kaplon H, Crescioli S, Chenoweth A, Visweswaraiah J, Reichert JM. Antibodies to watch in 2023. Mabs-austin. 2023;15(1):2153410. doi:10.1080/19420862.2022.2153410. PMID:36472472.
   PubMed Web of Science ®Google Scholar
• Carter PJ, Lazar GA. Next generation antibody drugs: pursuit of the ‘high-hanging fruit’. Nat Rev Drug Discov. 2018;17(3):197–14. doi:10.1038/nrd.2017.227. PMID:29192287.
   PubMed Web of Science ®Google Scholar
• The Antibody Society. Therapeutic monoclonal antibodies approved or in regulatory review. [accessed 2024 June 24]. www.antibodysociety.org/antibody-therapeutics-product-data.
   Google Scholar
• Dimasi JA, Feldman L, Seckler A, Wilson A. Trends in risks associated with new drug development: success rates for investigational drugs. Clin Pharmacol Ther. 2010;87(3):272–77. doi:10.1038/clpt.2009.295. PMID:20130567.
   PubMed Web of Science ®Google Scholar
• Reichert JM, Rosensweig CJ, Faden LB, Dewitz MC. Monoclonal antibody successes in the clinic. Nat Biotechnol. 2005;23(9):1073–78. doi:10.1038/nbt0905-1073. PMID:16151394.
   PubMed Web of Science ®Google Scholar
• Sawant MS, Streu CN, Wu L, Tessier PM. Toward Drug-Like Multispecific Antibodies by Design. Int J Mol Sci. 2020;21(20):7496. doi:10.3390/ijms21207496. PMID:33053650.
   PubMed Web of Science ®Google Scholar
• Reichert JM. Metrics for antibody therapeutics development. MAbs. 2010;2(6):695–700. dx.10.4161/mabs.2.6.13603. PMID:20930555.
   PubMed Web of Science ®Google Scholar
• Jain T, Sun T, Durand S, Hall A, Houston NR, Nett JH, Sharkey B, Bobrowicz B, Caffry I, Yu Y. et al. Biophysical properties of the clinical-stage antibody landscape. Proc Natl Acad Sci USA. 2017;114(5):944–49. doi:10.1073/pnas.1616408114. PMID:28096333.
   PubMed Web of Science ®Google Scholar
• Jiang XR, Song A, Bergelson S, Arroll T, Parekh B, May K, Chung S, Strouse R, Mire-Sluis A, Schenerman M. Advances in the assessment and control of the effector functions of therapeutic antibodies. Nat Rev Drug Discov. 2011;10(2):101–11. doi:10.1038/nrd3365. PMID:21283105.
   PubMed Web of Science ®Google Scholar
• Papadopoulos N, Martin J, Ruan Q, Rafique A, Rosconi MP, Shi E, Pyles EA, Yancopoulos GD, Stahl N, Wiegand SJ. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012;15(2):171–85. doi:10.1007/s10456-011-9249-6. PMID:22302382.
   PubMed Web of Science ®Google Scholar
• Cohenuram M, Saif MW. Panitumumab the first fully human monoclonal antibody: from the bench to the clinic. Anticancer Drugs. 2007;18(1):7–15. doi:10.1097/CAD.0b013e32800feecb. PMID:17159497.
   PubMed Web of Science ®Google Scholar
• Lee JY, Lee HT, Shin W, Chae J, Choi J, Kim SH, Lim H, Won Heo T, Park KY, Lee YJ. et al. Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy. Nat Commun. 2016;7(1):13354. doi:10.1038/ncomms13354. PMID:27796306.
   PubMedGoogle Scholar
• de Haij S, Jansen JH, Boross P, Beurskens FJ, Bakema JE, Bos DL, Martens A, Verbeek JS, Parren PW, van de Winkel Jg. et al. In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling. Cancer Res. 2010;70(8):3209–17. doi:10.1158/0008-5472.CAN-09-4109. PMID:20354182.
   PubMed Web of Science ®Google Scholar
• Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol. 2003;21(21):3940–47. doi:10.1200/JCO.2003.05.013. PMID:12975461.
   PubMed Web of Science ®Google Scholar
• Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 2002;99(3):754–58. doi:10.1182/blood.v99.3.754. PMID:11806974.
   PubMed Web of Science ®Google Scholar
• Alt N, Zhang TY, Motchnik P, Taticek R, Quarmby V, Schlothauer T, Beck H, Emrich T, Harris RJ. Determination of critical quality attributes for monoclonal antibodies using quality by design principles. Biologicals. 2016;44(5):291–305. doi:10.1016/j.biologicals.2016.06.005. PMID:27461239.
   PubMed Web of Science ®Google Scholar
• ICH. Guideline Q5C. Stability Testing of Biotechnological/Biological Products. International Conference on Harmonisation; 1996.
   Google Scholar
• ICH. Guideline Q6B. specifications: test procedures and acceptance criteria for biotechnological/biological products. International Conference on Harmonisation; 1999.
   Google Scholar
• Yang X, Xu W, Dukleska S, Benchaar S, Mengisen S, Antochshuk V, Cheung J, Mann L, Babadjanova Z, Rowand J. et al. Developability studies before initiation of process development: improving manufacturability of monoclonal antibodies. MAbs. 2013;5(5):787–94. doi:10.4161/mabs.25269. PMID:23883920.
   PubMed Web of Science ®Google Scholar
• United States Pharmacopeia. General Information/(1105)Immunological Test Methods-Surface Plasmon Resonance. USP-NF. Rockville, MD: United States Pharmacopeia; 2024. doi:10.31003/USPNF_M3070_03_01.
   Google Scholar
• Japanese Pharmacopoeia (JP17) General Information/Biotechnological/Biological Products-Surface Plasmon Resonance. 2474–78. 2016
   Google Scholar
• Haberger M, Bomans K, Diepold K, Hook M, Gassner J, Schlothauer T, Zwick A, Spick C, Kepert JF, Hienz B. et al. Assessment of chemical modifications of sites in the CDRs of recombinant antibodies: Susceptibility vs. functionality of critical quality attributes. MAbs. 2014;6(2):327–39. doi:10.4161/mabs.27876. PMID:24441081.
   PubMed Web of Science ®Google Scholar
• Schräml M, Biehl M. Kinetic screening in the antibody development process. Methods Mol Biol. 2012;901:171–81. doi:10.1007/978-1-61779-931-0_11. PMID:22723101.
   PubMedGoogle Scholar
• DiCara DM, Andersen N, Chan R, Ernst JA, Ayalon G, Lazar GA, Agard NJ, Hilderbrand A, Hötzel I. High-throughput screening of antibody variants for chemical stability: identification of deamidation-resistant mutants. MAbs. 2018;10(7):1073–83. doi:10.1080/19420862.2018.1504726. PMID: 30130444.
   PubMed Web of Science ®Google Scholar
• Karlsson R, Pol E, Å F. Comparison of surface plasmon resonance binding curves for characterization of protein interactions and analysis of screening data. Anal Biochem. 2016;502:53–63. doi:10.1016/j.ab.2016.03.007. PMID: 27019155.
   PubMed Web of Science ®Google Scholar
• Lietz CB, Deyanova E, Cho Y, Cordia J, Franc S, Kabro S, Wang S, Mikolon D, Banks DD. Identification of tyrosine sulfation in the variable region of a bispecific antibody and its effect on stability and biological activity. MAbs. 2023;15(1):2259289. doi:10.1080/19420862.2023.2259289. PMID: 37742207.
   PubMed Web of Science ®Google Scholar
• Chen L, Wang L, Shion H, Yu C, Yu YQ, Zhu L, Li M, Chen W, Gao K. In-depth structural characterization of Kadcyla® (ado-trastuzumab emtansine) and its biosimilar candidate. MAbs. 2016;8(7):1210–23. doi:10.1080/19420862.2016.1204502. PMID:27380163.
   PubMed Web of Science ®Google Scholar
• Vaish A, Lin JS, Hj M, Grandsard PJ, Chen Q. Binding affinity determination of therapeutic antibodies to membrane protein targets: Kinetic Exclusion Assay using cellular membranes for anti-CD20 antibody. Anal Biochem. 2020;609:113974. doi:10.1016/j.ab.2020.113974. PMID:33010205.
   PubMed Web of Science ®Google Scholar
• Yi M, Sun J, Sun H, Wang Y, Hou S, Jiang B, Xie Y, Ji R, Xue L, Ding X. et al. Identification and characterization of an unexpected isomerization motif in CDRH2 that affects antibody activity. MAbs. 2023;15(1):2215364. doi:10.1080/19420862.2023.2215364. PMID: 37229604.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. Analytical procedures and methods validation for drugs and biologics: guidance for industry. 2015.
   Google Scholar
• Rathore AS, Winkle H. Quality by design for biopharmaceuticals. Nat Biotechnol. 2009;27(1):26–34; dx.10.1038/nbt0109-26. PMID:19131992.
   PubMed Web of Science ®Google Scholar
• Xu Y, Wang D, Mason B, Rossomando T, Li N, Liu D, Cheung JK, Xu W, Raghava S, Katiyar A. et al. Structure, heterogeneity and developability assessment of therapeutic antibodies. MAbs. 2019;11(2):239–64. doi:10.1080/19420862.2018.1553476. PMID:30543482.
   PubMed Web of Science ®Google Scholar
• Raybould MIJ, Marks C, Krawczyk K, Taddese B, Nowak J, Lewis AP, Bujotzek A, Shi J, Deane CM. Five computational developability guidelines for therapeutic antibody profiling. Proc Natl Acad Sci USA. 2019;116(10):4025–30. doi:10.1073/pnas.1810576116. PMID:30765520.
   PubMed Web of Science ®Google Scholar
• Berkhout LC, l’Ami Mj, Ruwaard J, Hart MH, Heer PO, Bloem K, Nurmohamed MT, van Vollenhoven Rf, Boers M, Alvarez DF. et al. Dynamics of circulating TNF during adalimumab treatment using a drug-tolerant TNF assay. Sci Transl Med. 2019;11(477):eaat3356. doi:10.1126/scitranslmed.aat3356. PMID:30700574.
   PubMed Web of Science ®Google Scholar
• Harris RJ, Kabakoff B, Macchi FD, Shen FJ, Kwong M, Andya JD, Shire SJ, Bjork N, Totpal K, Chen AB. Identification of multiple sources of charge heterogeneity in a recombinant antibody. J Chromatogr B Biomed Sci Appl. 2001;752(2):233–45. doi:10.1016/s0378-4347(00)00548-x. PMID:11270864.
   PubMedGoogle Scholar
• Maadi H, Soheilifar MH, Choi WS, Moshtaghian A, Wang Z. Trastuzumab Mechanism of Action; 20 Years of Research to Unravel a Dilemma. Cancers (Basel). 2021;13(14):3540. doi:10.3390/cancers13143540. PMID:34298754.
   PubMed Web of Science ®Google Scholar